Job Description: Develop and execute a comprehensive territory business plan aligned with brand strategy and franchise priorities Drive demand generation across target HCP segments (e.g., geneticists, cardiologists, neurologists, metabolic specialists) Prioritize accounts using data-driven insights to optimize impact Deliver against sales objectives and key performance indicators (KPIs) for both Galafold and Pombiliti Opfolda Build and maintain strong, trust-based relationships with key customers and accounts Deliver high-quality, compliant product education aligned with approved messaging Engage customers across the patient journey, including diagnosis, treatment initiation, and long-term management Identify and address barriers to treatment, partnering cross-functionally to resolve access and operational challenges Drive initiatives to improve diagnosis and patient finding in Fabry and Pompe diseases Collaborate with stakeholders to expand awareness of disease and treatment options Support efforts to enhance cascade screening, referral pathways, and diagnostic rates Leverage digital tools to reinforce customer engagement and education Operate in full compliance with all company policies, legal regulations, and industry guidelines Demonstrate BioMarin’s values, with a strong focus on patient centricity and ethical conduct Requirements: Bachelor’s degree required 5+ years of pharmaceutical, biotech, or rare disease sales experience Proven track record of driving sales performance and achieving results in complex markets Strong account management and territory planning capabilities Experience engaging with specialty HCPs and navigating complex treatment pathways Experience in rare disease, specialty biologics, or enzyme therapies preferred Prior experience in Fabry disease, Pompe disease, or related therapeutic areas preferred Demonstrated ability to drive patient finding and market development initiatives preferred Experience working in highly cross-functional, matrixed organizations preferred Benefits: Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world.